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Abstract
Aims/hypothesis The hyperglycaemic clamp technique and the
frequently sampled IVGTT are unsuitable techniques to assess
beta cell function (BCF) in large cohorts. Therefore, the aim of
this study was to evaluate the discriminatory ability of simple
OGTT-based BCF indices for prediction of prediabetes (mean-
ing impaired fasting glucose and/or impaired glucose tolerance)
and type 2 diabetes.
Methods Glucose metabolism status was assessed by 2 h 75 g
OGTTat baseline (n=476, mean age 59.2 years, 38.7%wom-
en) and after 7 years of follow-up (n=416) in the Cohort on
Diabetes and Atherosclerosis Maastricht (CODAM) study
(1999–2009). Baseline plasma glucose, insulin and C-
peptide values during OGTTs were used to calculate 21 sim-
ple indices of BCF. Disposition indices (BCF index ×
Matsuda index), to compensate for the prevailing level of
insulin resistance, were calculated for the BCF indices with
the best discriminatory abilities. The discriminatory ability of
the BCF indices was estimated by the area under the receiver
operating characteristics curve (ROC AUC) with an outcome
of incident prediabetes (n=73) or type 2 diabetes (n=60 and
n= 18 cases, respectively, in individuals who were non-
diabetic or had normal glucose metabolism at baseline).
Results For incident prediabetes (n=73), all ROCAUCswere
less than 70%, whereas for incident type 2 diabetes, I30/I0,
CP30/CP0, ΔI30/ΔG30, ΔCP30/ΔG30 (where I, CP and G are
the plasma concentrations of insulin, C-peptide and glucose,
respectively, at the times indicated), and corrected insulin re-
sponse at 30 min had ROC AUCs over 70%. In at-baseline
non-diabetic individuals, disposition indices ΔI30/ΔG30,
ΔCP30/ΔG30 and corrected insulin response at 30 min had
ROC AUCs of over 80% for incident type 2 diabetes.
Moreover, these BCF disposition indices had significantly
better discriminatory abilities for incident type 2 diabetes than
the Matsuda index alone.
Conclusions/interpretation BCF indices reflecting early-
phase insulin secretion have the best ability to discriminate
individuals who will develop prediabetes and type 2 diabetes.
Of these, ΔCP30/ΔG30, often referred to as the C-
peptidogenic index, performed consistently well.
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BCF Beta cell function
CIRx Corrected insulin response measured x
min after the start of the OGTT
CODAM Cohort on Diabetes and Atherosclerosis
Maastricht
CPx C-peptide response measured x min after the
start of the OGTT
DI Disposition index
Gx Glucose response measured x min after the
start of the OGTT
Ix Insulin response measured x min after
the start of the OGTT
IQR Interquartile range
NGM Normal glucose metabolism
ROC Receiver operating characteristics
SQUASH Short Questionnaire to Assess
Health-enhancing Physical Activity
Introduction
Type 2 diabetes is characterised by reduced metabolic sensi-
tivity to insulin and insufficient insulin secretion by pancreatic
beta cells. Insulin resistance in itself is an insufficient cause of
type 2 diabetes, because of the pancreatic beta cells’ ability to
compensate for the prevailing level of insulin resistance by
increasing insulin secretion. However, if the beta cells are
unable to compensate for the prevailing insulin resistance,
hyperglycaemia arises and can cause a transition from NGM
to prediabetes, and eventually to type 2 diabetes [1–3].
The assessment of beta cell function (BCF) in vivo is com-
plex because of its interplay with other key variables in glucose
homeostasis, i.e. blood glucose levels, insulin sensitivity and
hepatic insulin extraction [2, 4]. The simplest methods for the
assessment of BCF in epidemiological studies are those based
on basal circulating levels of glucose, insulin and/or C-peptide,
such as HOMA-B [5]. Fasting levels, however, cannot provide
insight into the secretory response of beta cells to rising and
falling glucose concentrations [2, 3, 6]. Alternative approaches
are based on beta cell responses after administration of nutri-
ents, often glucose. Intravenous approaches include the
hyperglycaemic clamp technique and the frequently sampled
IVGTT. However, disadvantages of thesemethods are complex
protocols, high costs and the non-physiological route and pat-
tern of glucose administration [3, 6].
Oral administration of nutrients, as applied during an
OGTT or mixed-meal tolerance test, enables assessment of
the insulin secretory response under more physiological con-
ditions [6]. Both oral methods stimulate the incretin hormone
effect and allow for the simultaneous assessment of BCF,
insulin sensitivity and glucose metabolism status. The
mixed-meal tolerance test most closely tracks the
physiological responses that are expected to occur during an
individual’s normal day-to-day life (to a load of mixed nutri-
ents). The OGTT, however, can be standardised more easily
and is simple when it comes to administering the glucose load.
Therefore, the OGTT is often the preferred method in large
epidemiological studies.
Several simple BCF indices obtained from an OGTT have
been proposed and validated against intravenous methods,
with the major drawback of a non-physiologically triggered
insulin secretory response in the latter. Therefore, the objec-
tive of this study was to compare available, simple OGTT-
based BCF indices that use plasma concentrations of glucose,
insulin and/or C-peptide to identify their ability to discrimi-
nate glucose metabolism status (normal glucose metabolism
[NGM], prediabetes [meaning impaired fasting glucose and/or
impaired glucose tolerance] and type 2 diabetes), which may
approximate conceptually a more physiological aspect of BCF
assessment.
Methods
Study population and designWe used data from the Cohort
on Diabetes and Atherosclerosis Maastricht (CODAM) study,
a longitudinal observational study on the natural progression
of glucose tolerance [7]. CODAM includes 574 individuals
with an elevated risk of type 2 diabetes and cardiovascular
disease [8], who were extensively characterised at baseline
with regard to their lifestyle and cardiovascular and metabolic
profile during two visits to the university’s metabolic research
unit. After a median follow-up period of 7.0 years (interquar-
tile range [IQR] 6.9–7.1 years), 491 individuals participated in
the follow-up measurements (overall attrition rate 14%). The
participants who withdrew from the study during follow-up
had essentially the same baseline characteristics as the study
cohort. The CODAM study was approved by the Medical
Ethical Committee of the Maastricht University Medical
Center, and all participants gave written informed consent.
For the present analyses, we excluded 83 individuals with
previously diagnosed type 2 diabetes at baseline (defined as
self-reported diagnosis and/or use of glucose-lowering medi-
cation) who did not undergo an OGTTas per the protocol, and
15 individuals because of incomplete OGTT data. This result-
ed in a study population of 476 individuals, with glucose
metabolism ranging from NGM (n = 294) to prediabetes
(n=122) to newly diagnosed type 2 diabetes (n=60), using
the WHO criteria as specified below [9]. Longitudinal analy-
ses were restricted to individuals without type 2 diabetes who
participated in the follow-up measurements (n=294 NGM,
n=122 prediabetes), of whom 73 (24.8%) individuals with
NGM progressed to prediabetes, and 17 (5.8%) individuals
with NGM and 46 (37.7%) with prediabetes progressed to
type 2 diabetes.
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OGTT and glucose metabolism status After an overnight
fast (>12 h), venous blood samples were collected before
and 30, 60 and 120 min after ingestion of 75 g glucose.
Plasma for the assessment of insulin and C-peptide was col-
lected in EDTA tubes on ice, separated after centrifugation
(3000×g for 15 min at 4°C), and stored at −80°C until the
assays were performed. The time between collection and stor-
age was less than 2 h.
Insulin and C-peptide were measured by use of a custom
Meso Scale Discovery duplex array (Meso Scale Discovery,
Gaithersburg, MD, USA; www.mesoscale.com). In short, 96
well-plates, with capture antibodies against insulin and
C-peptide patterned on distinct spots in the same well were
supplied by the manufacturer. Samples (10 μl/well), detection
antibodies and read buffer for electrochemiluminescence were
applied according to manufacturer’s instruction, and plates
were read using a SECTOR Imager 2400 (Meso Scale
Discovery). The detection ranges of the assay were
35–25,000 pg/ml for insulin and 70–50,000 pg/ml for C-pep-
tide. Interassay CVs for insulin and C-peptide were 9.7% and
7.9%, respectively. Insulin and C-peptide values were con-
verted from pg/ml to pmol/l using a molar mass of 5808 g
for insulin and 3010 g for C-peptide. Plasma for the assess-
ment of glucose was collected in NaF/KOx tubes on ice.
Glucose was measured by use of the hexokinase method
(HK-G6PD method; Glucose HK 125; ABX Diagnostics,
Montpellier, France).
Glucose metabolism status was defined according to the
WHO 2006 criteria [9]: NGM (fasting plasma glucose
<6.1 mmol/l and 2 h post-load plasma glucose <7.8 mmol/l),
prediabetes (fasting plasma glucose levels of 6.1–6.9 mmol/l
and/or 2 h post-load glucose levels of 7.8–11.1 mmol/l) and
type 2 diabetes (fasting plasma glucose ≥7.0 mmol/l and/or
2 h post-load glucose ≥11.1 mmol/l).
OGTT-derived measures of BCF Available OGTT-based
BCF indices were extracted from the literature and included
nine early-phase measures (based on the first 30 min of the
OGTT), six late-phase measures (based on the fasting condi-
tion combined with the last 60–120 min of the OGTT) and
two overall insulin secretion measures (based on all OGTT
sampling points) (Table 1).
Kahn et al identified a hyperbolic relationship between in-
sulin sensitivity and secretion [10]. The product of insulin sen-
sitivity and insulin secretion is called the disposition index (DI)
and reflects a measure of BCF corrected for the degree of in-
sulin sensitivity. In this study, the Matsuda index was used as a
measure of insulin sensitivity (Matsuda index: 10,000 / √G0 ×
I0 × mean G × mean I; where G and I are the plasma glucose
and insulin values, respectively, at the time indicated) [11].
The OGTT-based mathematical model of Mari et al [12]
describes insulin secretion as the sum of two components.
Glucose sensitivity describes the degree of pancreatic beta cell
responsiveness to absolute blood glucose levels (glucose–in-
sulin dose–response curve). The beta cell potentiation factor
modulates the dose–response curve as a positive function of
time in individuals with NGM. The second component of
insulin secretion is beta cell rate sensitivity, which represents
early-phase insulin release. We evaluated these mathematical
model-based BCF indices as additional analyses as these BCF
components cannot be assessed by simple BCF indices.
Study population characteristics Body height (cm) and
weight (kg) were measured to the nearest 1 cm and 0.1 kg
with the participants wearing light clothing and no shoes [7].
Total cholesterol, HDL-cholesterol and triacylglycerol were
determined using enzymatic techniques (Roche Diagnostics,
Mannheim, Germany). LDL-cholesterol was calculated using
the Friedewald formula [13]. NEFA were assessed in EDTA
plasma using an enzymatic colorimetric method (NEFA-C;
Wako Chemicals, Neuss, Germany) [14]. Blood pressure
was measured using an oscillometric precision blood pressure
instrument (Maxi-Stabol 3; Speidel & Keller, now Welch
Allyn, Skaneateles Falls, NY, USA) [15]. Smoking status,
medication use and the prevalence of a history of cardiovas-
cular disease and cardiovascular events were determined by
self-report [16]. Physical activity was measured by the vali-
dated Short Questionnaire to Assess Health-enhancing
Physical Activity (SQUASH) [17].
Statistical methods All analyses were performed using the
software package SPSS statistics version 22.0 for Windows
(SPSS, IBM Corp, Armonk, NY, USA). Differences in medi-
an BCF across glucose metabolism groups were tested by
Kruskal–Wallis and Mann–Whitney U tests.
The primary outcome was the discriminatory ability of the
BCF indices to predict prediabetes and type 2 diabetes. The
discriminatory ability was assessed by use of the area under
the receiver operating characteristics (ROC) curve with either
non-prediabetes (i.e. NGM) or non-diabetes as the reference
category. Differences between consecutively ranked ROC
AUCs were tested by the algorithm developed by DeLong
et al [18]. ROC AUCs of the DIs (the products of the BCF
index andMatsuda index) were assessed for BCF indices with
ROC AUCs of 0.70 or above for incident prediabetes and/or
type 2 diabetes [19].
Additional analyses were performed to cross-sectionally
evaluate the discriminatory abilities of the BCF indices for
prevalent prediabetes and type 2 diabetes. Finally, the discrim-
inatory ability of the mathematical model variables of Mari
et al [12] were evaluated: beta cell glucose sensitivity, beta cell
rate sensitivity and beta cell potentiation factor.
The confidence level used in the statistical analyses was
95%, corresponding to a p value of 0.05.
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Results
The median age was similar across groups of glucose metab-
olism status at baseline (Table 2). The male to female ratio was
higher in participants with type 2 diabetes. Median fasting and
2 h post-load plasma concentrations of glucose and insulin,
and HbA1c increased in the order NGM to prediabetes to type
2 diabetes, whereas median insulin sensitivity decreased with
impairment of glucose metabolism. Furthermore, BP in-
creased and the lipid profile worsened with impairment of
glucose metabolism. In addition, the proportion of current
smokers was lowest among individuals with type 2 diabetes,
but individuals with prediabetes or type 2 diabetes were less
physically active than individuals with NGM (Table 2).
Overall, the median values of all BCF indices differed sta-
tistically significantly by glucose metabolism status at
baseline, reflecting the fact that impaired BCF went along
with impairment of glucose metabolism (Table 3). For most
indices, the largest proportional difference in BCF was ob-
served between individuals with prediabetes and type 2
diabetes.
Incident prediabetes and type 2 diabetes Of the individuals
with NGM or prediabetes at baseline, 63 (17 NGM and 46
prediabetes) progressed to type 2 diabetes at follow-up, and 73
individuals with NGM progressed to prediabetes at follow-up
(Table 4).
ROC AUCs for incident type 2 diabetes revealed estimates
higher than 70% for I30/I0, CP30/CP0, ΔCP30/ΔG30 and
corrected insulin response at 30 min (CIR30), with ROC
AUCs ranging between 74% and 81% (Table 4). Restricting
the population to individuals who had NGM at baseline did





HOMA-B1 (%) [5] (20 × I0)/(G0 - 3.5)
HOMA-B2 (%) [32] Web-based calculator using the HOMA2 model [33]
Insulin:glucose ratio t0 [34] I0/G0
C-peptide:glucose ratio t0 [35] CP0/G0
Early-phase indices
Insulin ratio t30 [36] I30/I0
C-peptide ratio t30 [36] CP30/CP0
Insulinogenic index t30 [35] (I30 - I0)/(G30 - G0)
Modified insulinogenic index t30 [37] (I30 - I0)/(G30)
C-peptidogenic index t30 [35] (CP30 - CP0)/(G30 - G0)
CIR30 × 10
−2 [38] I30/[G30 × (G30 - 3.89)]
Stumvoll early-phase × 10−2 [39] 1283+ (1.829 × I30) - (138.7 ×G30) + (3.772 × I0)
BIGTT-AIR0.30.120 × 10
−2 [40] Exp[8.20 + (0.00178 × I0) + (0.00168 × I30 ) - (0.000383× I120) - (0.314 ×G0) -
(0.109 ×G30) + (0.0781×G120) + (0.180 × sex) - (0.032 ×BMI)]
BIGTT-AIR0.60.120 × 10
−2 [40] Exp[8.19 + (0.00339 × I0) + (0.00152 × I60) - (0.000959× I120) - (0.389 ×G0) -
(0.142 ×G60) + (0.164 ×G120) + (0.256 × sex) + (0.038 ×BMI)]
Late-phase indices
Stumvoll second phase [39] 287 + (0.4164× I30) - (26.07 ×G30) + (0.9226× I0)
Insulin ratio t120 [36] I120/I0
C-peptide ratio t120 [36] CP120/CP0
Insulinogenic index t120 [35] (I120 - I0)/(G120 - G0)
C-peptidogenic index t120 [35] (CP120 - CP0)/(G120 - G0)
CIR120 × 10
−2 [38] I120/(G120 × (G120 - 3.89))
Overall indices
AUC insulin:glucose ratio [41] [(30 - 0) × (I0 + I30)/2] + [(60 - 30) × ( I30 + I60) / 2] + [(120 - 60) × ( I60 × I120)/2)] / [(30 -
0) × (G0 +G30) / 2] + [(60 - 30) × ( G30 +G60) / 2] + [(120 - 60) × ( G60 ×G120) / 2]
AUC C-peptide:glucose ratio [41] [(30 - 0) × (CP0 +CP30) /2] + [(60 - 30) × (CP30 +CP60) / 2] + [(120 - 60) × (CP60 ×CP120)
/2)] / [(30 - 0) × (G0 +G30) / 2] + [(60 - 30) × (G30 +G60) / 2) + ((120 - 60) ×
(G60 ×G120) / 2)]
BIGTT-AIR, beta cell function, insulin sensitivity and glucose tolerance testing; t, time point during OGTT, min in subscript
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not materially alter the results; the same five BCF indices and
CP0/G0 had ROC AUCs higher than 70% (AUCs 70–84%).
For incident prediabetes, the ROC AUCs of all BCF indices
were less than 70%.
After calculating the DIs, the ROC AUCs for ΔI30/ΔG30,
ΔCP30/ΔG30 and CIR30 had the best discriminatory abilities
(Fig. 1; see electronic supplementary material [ESM] Fig. 1
for ROC characteristics). Moreover, for incident type 2 diabe-
tes, these BCF DIs had significantly better abilities than the
Matsuda index alone (Fig. 1a).
Additional analyses The ability of all BCF indices to cross-
sectionally discriminate between glucose metabolism groups
was evaluated. ROC AUCs for type 2 diabetes revealed esti-
mates higher than 70% for all early-phase indices, the late-
phase index CIR120 and the two overall insulin secretion indi-
ces (ESM Table 1). The five indices that were ranked highest
in the prospective analyses for incident type 2 diabetes, in
individuals who were non-diabetic or had NGM at baseline,
also showed high ROC AUCs in the cross-sectional
analyses, with ROC AUCs in the range 78–88% and 82–
92%, respectively. The three DIs that were ranked highest in
the longitudinal analyses, ΔI30/ΔG30, ΔCP30/ΔG30 and
CIR30, also had the best ROC AUCs in the cross-sectional
analyses (data not shown).
In individuals who were non-diabetic or had NGM at base-
line, only the mathematical model variable of beta cell glucose
sensitivity was able to discriminate incident type 2 diabetes
(ROC AUCs of 78% for both groups). Compared with the
simple BCF indices, only the C-peptidogenic index had better
discriminatory abilities than beta cell glucose sensitivity for
predicting incident type 2 diabetes. ROC AUCs of rate sensi-
tivity and potentiation factor ratio were less than 70% (data
not shown).
Discussion
In this study, for incident prediabetes and type 2 diabetes, the
discriminatory ability of available simple OGTT-based indices
Table 2 Baseline characteristics:
individuals with NGM, prediabe-








Age (years) 59.7 (53.0, 64.2) 60.8 (55.3, 64.9) 60.1 (56.3, 64.1)
Women, n (%) 120 (40.8) 47 (38.5) 17 (27.9)
BMI (kg/m2) 27.3 (25.0, 29.5) 28.0 (26.5, 31.2) 30.6 (26.6, 32.8)
Current smoker, n (%) 60 (20.4) 22 (18.0) 9 (14.8)
Physical activity (103 ×METs/week) 6.54 (3.94, 8.94) 5.10 (2.79, 8.46) 5.64 (3.73, 7.78)
Systolic BP (mmHg) 133 (122, 146) 141 (132, 155) 145 (136, 158)
Diastolic BP (mmHg) 80.0 (73.5, 85.0) 82.8 (78.0, 91.5) 85.0 (79.5, 92.8)
Antihypertensive medication, n (%) 82 (27.9) 52 (42.6) 29 (47.5)
CVD, n (%) 68 (23.1) 34 (28.1) 24 (39.3)
CVE, n (%) 40 (13.6) 20 (16.5) 11 (18.0)
Total cholesterol (mmol/l) 5.20 (4.60, 5.80) 5.20 (4.60, 5.83) 5.50 (4.90, 6.00)
HDL-cholesterol (mmol/l) 1.23 (1.01, 1.44) 1.09 (0.93, 1.37) 0.97 (0.86, 1.20)
LDL-cholesterol (mmol/l) 3.30 (2.80, 3.90) 3.35 (2.80, 4.30) 3.50 (2.90, 3.98)
HDL:LDL ratio 0.37 (0.28, 0.48) 0.32 (0.26, 0.45) 0.30 (0.24, 0.37)
Triacylglycerol (mmol/l) 1.20 (0.90, 1.60) 1.60 (1.10, 2.10) 1.90 (1.30, 2.65)
NEFA (mmol/l) 0.49 (0.38, 0.57) 0.53 (0.43, 0.64) 0.55 (0.45, 0.70)
Lipid-lowering medication, n (%) 44 (15.0) 24 (19.7) 9 (14.8)
HbA1c (%) 5.70 (5.40, 5.90) 5.80 (5.60, 6.10) 6.40 (5.90, 6.90)
HbA1c (mmol/mol) 38.0 (35.0, 40.0) 39.0 (37.0, 43.0) 46.0 (40.0, 51.0)
Fasting glucose (mmol/l) 5.27 (5.00, 5.53) 6.00 (5.54, 6.30) 7.14 (6.81, 7.95)
Fasting insulin (pmol/l) 61.2 (45.2, 87.4) 78.8 (51.4, 133) 110 (66.1, 159)
2 h glucose (mmol/l) 5.65 (4.65, 6.54) 8.79 (7.82, 9.90) 12.3 (11.1, 14.7)
2 h insulin (pmol/l) 352 (211, 589) 664 (424, 1176) 744 (489, 1017)
Matsuda index of insulin sensitivity 3.57 (2.45, 4.95) 2.46 (1.39, 3.63) 1.45 (1.09, 2.66)
Values are expressed as median (IQR) or n (%)
CVD, self-reported cardiovascular disease; CVE, self-reported cardiovascular event; MET, metabolic equivalent
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of BCF was evaluated after a median follow-up period of
7 years. Overall, early-phase indices of BCF, typically based
on the insulin response in the first 30 min of the OGTT, per-
formed best.
The better ability of early-phase BCF indices to discrimi-
nate glucose metabolism status is in line with previous vali-
dation studies, which used the frequently sampled IVGTT or
incident type 2 diabetes as reference standards [20, 21].
Moreover, this finding corresponds with an earlier and stron-
ger deterioration of the early-phase secretory response in the
pathogenesis of type 2 diabetes [1, 22]. The BCF indices
ranked highest in our study also performed well in the evalu-
ations of Hanson et al [20] and Lorenzo et al [21]. In general,
discriminatory abilities of BCF indices using C-peptide were
better than those using insulin in a similar formula. This can be
explained by the fact that insulin concentrations assessed in
peripheral blood do not perfectly reflect insulin secretion by
the pancreas. Pancreatic beta cells secrete insulin into the por-
tal vein perfusing the liver, where insulin is partially cleared
prior to entering the peripheral circulation [2–4]. A more valid
estimation of prehepatic insulin secretion can be obtained
from C-peptide, which is co-secreted with insulin in equimo-
lar amounts and avoids hepatic degradation [2–4].
For prediabetes, we observed a lower discriminatory ability
of the BCF indices than was seen for type 2 diabetes. This
probably reflects the gradual deterioration of BCF during the
pathogenesis of type 2 diabetes. In prediabetic individuals,
insulin secretion is still sufficient to compensate for a certain
level of insulin resistance and to maintain glucose levels with-
in the non-diabetic range [2, 23]. In our data, more detailed
analyses of the subtypes of prediabetes, i.e. impaired fasting
glucose and impaired glucose tolerance, revealed a trend









HOMA-B1 (%) 105.39 (74.60, 144.20) 99.78 (64.62, 169.02) 88.58 (53.25, 118.20)† 0.037
HOMA-B2 (%) 96.90 (76.70, 119.35) 92.00 (67.20, 133.83) * 79.40 (55.75, 98.25)† 0.001
I0/G0 ratio
b 11.45 (8.55, 16.4) 13.21 (8.58, 13.13) 15.82 (9.69, 21.22)†§ 0.007
CP0/G0 ratio
b 0.12 (0.95, 0.15) 0.13 (0.10, 0.18) 0.14 (0.12, 0.17)†§ 0.016
Early-phase BCF indices
I30/I0 ratio 7.98 (6.14, 10.4) 5.81 (4.61, 7.42)* 3.62 (2.74, 3.62)
†§ <0.001
CP30/CP0 ratio 3.38 (2.91, 4.22) 2.68 (2.25, 3.30)* 1.96 (1.74, 2.38)
†§ <0.001
ΔI30/ΔG30 ratio 135.50 (88.27, 198.93)* 90.75 (53.81, 151.89)* 58.02 (38.11, 85.16)
†§ <0.001
ΔCP30/ΔG30 ratio 0.49 (0.33, 0.66) 0.30 (0.23, 0.42)* 0.19 (0.15, 0.26)
†§ <0.001
CIR30 × 10
−2 12.91 (8.29, 19.15) 8.02 (4.34, 11.54)* 3.68 (2.72, 5.86)†§ <0.001
Stumvoll first phase × 10−2 12.53 (9.33, 16.76) 10.83 (6.08, 17.51)* 7.08 (4.08, 12.56)†§ <0.001
BIGTT-AIR0.30.120 × 10
−2 29.64 (21.98, 43.84) 24.11 (15.36, 37.02)* 17.33 (11.77, 24.90)†§ <0.001
BIGTT-AIR0.60.120 × 10
−2 34.00 (25.81, 51.12) 27.32 (17.08, 44.66)* 19.42 (12.37, 31.24)†§ <0.001
Late-phase BCF indices
Stumvoll second phase 330.71 (258.45, 431.44) 310.64 (187.11, 457.80)* 239.06 (152.97, 358.97)† <0.001
I120/I0 ratio 5.60 (3.77, 8.27) 8.42 (5.94, 11.7)* 6.85 (4.32, 10.37)
†§ <0.001
CP120/CP0 ratio 4.04 (3.21, 5.08) 4.51 (3.64, 5.60) 3.73 (2.59, 5.31)
§ <0.001
ΔI120/ΔG120 ratio 235.21 (, 122.49, 532.01) 200.50 (113.36, 403.98)* 114.48 (66.54, 178.28) 0.037
ΔCP120/ΔG120 ratio 1.35 (, 1.29, 2.83) 0.91 (0.59, 1.32)* 0.47 (0.31, 0.67)
† 0.009
CIR120 × 10
−2 35.21 (21.38, 60.71) 17.45 (11.13, 31.92)* 7.29 (4.42, 7.29)†§ <0.001
Overall indices
IAUC / GAUC ratio 62.03 (45.50, 86.60) 56.71 (35.91, 93.40)* 42.27 (26.70, 63.07)
† <0.001
CPAUC/ GAUC ratio 0.35 (0.26, 0.38) 0.28 (0.21, 0.37)* 0.20 (0.16, 0.24)
† <0.001
Values are expressed as median (IQR)
a p value of Kruskal–Wallis test
b A higher value indicates impairment of BCF, unlike other BCF indices
*Statistically significant difference IGM vs NGM, p value of Mann–Whitney U test <0.05; † statistically significant difference T2DM vs NGM, p value
of Mann–Whitney U test <0.05; § statistically significant difference T2DM vs IGM, p value of Mann–Whitney U test <0.05
BIGTT-AIR, beta cell function, insulin sensitivity and glucose tolerance testing; T2DM, type 2 diabetes mellitus
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towards higher ROCAUCs for individuals with impaired glu-
cose tolerance relative to those with NGM than for individuals
with impaired fasting glucose relative to NGM (data not
shown). This is in line with the post-load glucose metabolism
of individuals with impaired fasting glucose being normal,
reflecting an adequate (compensatory) post-load BCF.
Future studies that focus on estimates of insulin secretory
function in prediabetes subtypes may provide novel insights
into the aspects of BCF covered by the several BCF indices.
In line with previous findings [24, 25], discriminatory abil-
ities of the oral DIs CIR30 and ΔI30/ΔG30 were significantly
better than those of the isolated BCF indices in the current
study. Moreover, discriminatory abilities of the oral DIs were
better than those of the Matsuda index alone, especially the
DIs of ΔI30/ΔG30, ΔCP30/ΔG30 and CIR30. This suggests
that ΔI30/ΔG30, ΔCP30/ΔG30 and CIR30 contributed
significantly to the discrimination of glucose metabolism
groups, on top of insulin sensitivity. This indicates specific
features of BCF irrespective of insulin sensitivity.
ROC analyses of logistic regression outcomes of the BCF
indices with the Matsuda index as a covariate (using the prob-
abilities predicted by the regression model) revealed similar
results, as presented in Fig. 1 (data not shown). Theoretically,
a hyperbolic function between BCF and insulin sensitivity has
been suggested as a requirement to apply the DIs. In our data,
such a hyperbolic function between any of the BCF indices and
a measure of insulin sensitivity (e.g. the Matsuda index,
HOMA-IR or the insulin sensitivity index (SI0,120)] was not
present [data not shown]). This is in line with some other stud-
ies [26, 27], but there are studies that have established a hyper-
bolic function between BCF and insulin sensitivity [26, 28]. In
addition, artificial relations between indices of BCF and insulin
Table 4 Discrimination between individuals with incident type 2 diabetes mellitus (T2DM) or prediabetes in individuals who were NGM or non-
T2DM at baseline





Rank Incident T2DM in
at-baseline NGM
Follow-up
n = 17 T2DM
n = 170 NGM







HOMA-B1 52 (44, 61) 20 64 (48, 81) 9 54 (46, 62) 15
HOMA-B2 52 (43, 60) 21 65 (48, 82) 8 53 (45, 62) 16
I0/G0 ratio 59 (51, 67) 16 69 (54, 85) 7 51 (43, 60) 20
CP0/G0 ratio 60 (52, 68) 14 70 (55, 84) 6 52 (44, 60) 19
Early-phase BCF indices
I30/I0 ratio 77 (70, 83) 4 72 (60, 84) 5 55 (47, 63) 9–11
CP30/CP0 ratio 78 (72, 84) 2 76 (65, 87) 3 50 (43, 58) 21
ΔI30/ΔG30 ratio 74 (68, 81) 5 73 (61, 85) 4 59 (51, 67) 5
ΔI30/G30 ratio 69 (62, 77) 6 63 (49, 77) 10 55 (47, 63) 9–11
ΔCP30/ΔG30 ratio 81 (75, 86) 1 84 (75, 93) 1 62 (54, 70) 2–3
CIR30 77 (71, 83) 3 77 (67, 87) 2 61 (53, 68) 4
Stumvoll early-phase × 10−2 62 (54, 71) 10 52 (36, 69) 18 55 (47, 63) 9–11
BIGTT0.30.120 × 10
−2 63 (55, 71) 9 58 (42, 73) 12 54 (46, 63) 13–14
BIGTT0.60.120 × 10
−2 61 (52, 69) 12 51 (33, 69) 20 57 (49, 65) 6
Late-phase BCF indices
Stumvoll second phase 60 (52, 69) 13 50 (33, 67) 21 54 (46, 63) 13–14
I120/I0 ratio 60 (52, 67) 15 51 (35, 66) 19 63 (55, 71) 1
CP120/CP0 ratio 54 (46, 62) 18 56 (41, 71) 13 62 (54, 70) 2–3
ΔI120/ΔG120 ratio 54 (47, 61) 17 54 (39, 69) 15 55 (48, 63) 8
ΔCP120/ΔG120 ratio 52 (48, 58) 19 52 (39, 65) 17 55 (47, 62) 12
CIR120 65 (57, 73) 8 56 (40, 72) 14 52 (45, 60) 17
Overall insulin secretion indices
IAUC/ GAUC ratio 61 (53, 70) 11 53 (37, 69) 16 52 (44, 61) 18
CPAUC/ GAUC ratio 68 (60, 76) 7 63 (48, 78) 11 56 (47, 64) 7
ROC AUCs are expressed in % (95% CI)
‘Rank’ reflects the order of ROC AUC estimates from high to low. Differences between ranked ROC AUCs were not statistically significant
BIGTT-AIR, beta cell function, insulin sensitivity and glucose tolerance testing
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sensitivity may arise when these indices are obtained from
insulin and glucose concentrations during a single OGTT [26,
29]. In this case, the DIs should be calculated with caution.
We found that the C-peptidogenic index (ΔCP30/ΔG30) per-
formed better than the mathematical model variables in the pres-
ent study. However, the good performance of the C-peptidogenic
index does not necessarily imply a weakness of the modelling
analysis. The reason is that the mathematical model measures
specific aspects of BCF (beta cell glucose sensitivity, beta cell
potentiation ratio and beta cell rate sensitivity), which together
determine glucose metabolism. In contrast, beta cell glucose
sensitivity and beta cell rate sensitivity, which have been shown
to be relatively independent and both potentially important pre-
dictors of type 2 diabetes, are lumped together in the C-
peptidogenic index [30]. This may confer on the empirical index
a relative advantage in terms of predictive power.
The present study benefits from the comparison of all avail-
able BCF indices in one study population, which includes
individuals with NGM, prediabetes and newly diagnosed type
2 diabetes. Moreover, the study has a longitudinal set-up with
7 years of follow-up. Furthermore, the assessment of plasma
C-peptide concentrations enabled comparative analyses be-
tween BCF indices based on insulin and C-peptide concentra-
tions. Some limitations also merit discussion. First, glucose
metabolism status, BCF and insulin sensitivity were all ob-
tained from a single OGTT [31]. We aimed to minimise auto-
correlation between BCF and insulin sensitivity by using the
Matsuda index, which is based on fasting and mean plasma
insulin and glucose concentrations during the OGTT, rather
than on concentrations at specific time points only. Although
our interest was in discrimination, and not in association esti-
mates, correlations between the BCF indices and the Matsuda
index were very weak overall, and additional multicollinearity
diagnostics (i.e. the variance inflation factor) were negative.
Finally, CODAM participants have a higher risk of type 2
diabetes than the general population, so generalisability might
be limited. However, as the differences in BCF between non-
diabetic and type 2 diabetic individuals in the present study
population may be smaller than in the general population, the
discriminatory abilities of the BCF indices in the general pop-
ulation may be larger.
In summary, early-phase BCF indices obtained from an
OGTT revealed those with the best abilities to discriminate
glucose metabolism status. Overall, the C-peptidogenic index
(ΔCP30/ΔG30) had the best discriminatory ability. If the degree
of insulin sensitivity is taken into account by calculating the
DIs, the insulinogenic index (ΔI30/ΔG30), the C-peptidogenic
index (ΔCP30/ΔG30) and CIR30 had the highest ability to dis-
criminate glucose metabolism status. Based on our results, we
recommend the C-peptidogenic index (ΔCP30/ΔG30) for
assessing BCF in epidemiological studies. However, the pre-
ferred combination of BCF indices reflecting different aspects
of insulin secretory function should be determined in view of
the specific objectives and hypotheses of the study.
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Fig. 1 ROC AUCs and corresponding 95% CIs of the oral DIs for: (a)
discriminatory abilities for incident type 2 diabetes mellitus (T2DM) in
at-baseline non-T2DM; (b) discriminatory abilities for incident T2DM in
at-baseline NGM; and (c) discriminatory abilities for incident prediabetes
in at-baseline NGM, CODAM study, Maastricht, the Netherlands, 1999–
2009. Dashed line, ROCAUC 50%. *p < 0.05 for ROCAUC vsMatsuda
index alone
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